

**April 17, 2024**

**The High-Cost Specialty Drug Kynamro is no longer reinsured under the BIO case type effective 3/22/2024 since it was not approved by the FDA as of**

**August 2019.**

**Per AHCCCS Financial Review the following**

**High-Cost Specialty Drugs will no longer be reinsured under the BIO Case type effective 10/01/2024 due to underutilization:**

* **Novoseven**
* **Kuvan**